Table 3.
Parameters | No | No of events | HR (95% CIa) | p-valueb |
---|---|---|---|---|
Age (years) |
|
|
1.695 (0.743-3.875) |
0.211 |
<50 |
24 |
8 |
|
|
≥ 50 |
39 |
19 |
|
|
Gender |
|
|
0.596 (0.225-1.575) |
0.297 |
Male |
47 |
22 |
|
|
Female |
16 |
5 |
|
|
Histology |
|
|
0.930 (0.431-.006) |
0.854 |
WHO type II |
37 |
16 |
|
|
WHO type III |
26 |
11 |
|
|
Primary tumor (T) |
|
|
5.091 (2.350-11.030) |
<0.001 |
T1-T2 |
44 |
12 |
|
|
T3-T4 |
19 |
15 |
|
|
Nodal status (N) |
|
|
2.780 (1.302-5.934) |
0.009 |
N0-N1 |
41 |
13 |
|
|
N2-N3 |
22 |
14 |
|
|
AJCC staging |
|
|
4.464 (1.879-10.607) |
0.001 |
Stage I-II |
31 |
7 |
|
|
Stage III-IV |
32 |
20 |
|
|
FLJ10540 |
|
|
4.741 (2.177-10.326) |
<0.001 |
Low expression |
42 |
11 |
|
|
High-expression |
21 |
16 |
|
|
Osteopontin |
|
|
5.012 (2.315-10.850) |
<0.001 |
Low expression |
47 |
14 |
|
|
High-expression | 16 | 13 |
Abbreviations: HR Hazard Ratio, WHO World Healthy Organization; AJCC American Joint Committee on Cancer.
a 95% Wald Confidence Limits.
b Associations determined by Cox regression analyses. Statistically significant (p < 0.05).